Phase I study of nedaplatin and S-1 in patients with advanced or relapsed squamous cell lung cancer

Phase I study of nedaplatin and S-1 in patients with advanced or relapsed squamous cell lung cancer - Phase I study of nedaplatin and S-1 in patients with advanced or relapsed squamous cell lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000036387

Enrollment

Registered

2019-04-02

Start date

2012-07-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Squamous cell lung cancer

Interventions

Nedaplatin is administered on day 1 and S-1 is administered for 2 weeks (day 1 to 14).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Histologically or cytologically confirmed squamous cell lung cancer. 2)stage III-IV without indication of curative radiotherapy and surgery, or relapsed case after surgery. 3)no more than 75 years-old 4)PS 0-1

Exclusion criteria

Exclusion criteria: 1)Severe complication 2)interstitial penumonia 3)positive for HBs antigen 4)Pleural effusion, ascites, or pericardial effusion which need drainage 5)double malignancy

Design outcomes

Primary

Measure	Time frame
determination of maximum dose and estimation of recommendation dose	—

Countries

Japan

Contacts

Public ContactNobuhiro Kanaji

Kagawa University Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine

kanaji@med.kagawa-u.ac.jp087-891-2145

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026